Cognizant will offer solutions across key growth areas, including enterprise AI agents, tailored industry large language models and infrastructure with NVIDIA AI. TEANECK, N.J.

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient.

Ellington Credit Company has shifted from a mortgage REIT to a closed-end fund focusing on high-yield CLOs, aiming for substantial gains. Despite potential high rewards, EARN's transition brings significant risks, with recent earnings volatility and a hefty debt load posing challenges. EARN's valuation appears attractive, trading at a discount with a low P/E ratio, suggesting potential upside if management successfully navigates the CLO market.

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion.

COLUMBUS, Ohio , March 24, 2025 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) today announced the pricing of a registered underwritten offering of 19,607,844 shares of its common stock at a price to the public of $102.00 per share. Subject to certain conditions, all shares are expected to be borrowed by the forward counterparties (as defined below) (or their respective affiliates) from third parties and sold to the underwriters and offered in connection with the forward sale agreements described below.

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Integral Ad Science Holding Corp. (NASDAQ:IAS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/integral-ad-science-lawsuit-submission-form?prid=138447&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Fluence Energy, Inc. (NASDAQ:FLNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=138448&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your e.l.f. Beauty, Inc. (NYSE:ELF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/e-l-f-beauty-lawsuit-submission-form?prid=138449&wire=1 or contact Joseph E.

Despite recent struggles in the RV industry, Winnebago Industries remains a 'buy' due to its attractive valuation and potential for recovery. Revenue and deliveries have declined, but management's optimistic projections for 2025 suggest potential improvement in earnings and revenue. Macroeconomic challenges like inflation and high interest rates have impacted consumer spending, yet the company still generates positive cash flow.

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business Combination which was previously announced on December 18, 2023 and ultimately closed on March 14, 2024. The Rescission Agreement and its effects are subject to certain closing conditions, including Entero receiving shareholder approval which must …

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Ready Capital Corporation (NYSE:RC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ready-capital-corporation-lawsuit-submission-form?prid=138446&wire=1 or contact Joseph E. Levi, Esq.

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions (NYSE: ULS) today announced that LG Display's organic light-emitting diode (OLED) televisions and monitors have achieved UL Solutions Eyesafe Verification, a global first, confirming the accuracy and reliability of LG Display's marketing claims that their OLED models effectively reduce circadian-stimulating blue light emissions. “UL Solutions' Marketing Claim Verification process is designed to give consumers confidence in product claims,” said To.

New Gold reported its highest production in 2024, with 80,400 ounces of gold and 14.5 million pounds of copper in Q4, driven by higher feed grades. Production is expected to increase in 2025 and beyond, driving New Gold's growth. Increased margins and cash flow growth, coupled with a positive outlook for copper and gold prices, provide a strong tailwind for NGD.

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / March 24, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Fluence Energy, Inc. (NasdaqGS:FLNC), if they purchased the Company's shares between November 29, 2023, and February 10, 2025, inclusive (the "Class Period").

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / March 24, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 31, 2025 to file lead plaintiff applications in a securities class action lawsuit against Integral Ad Science Holding Corp. (the "Company") (NasdaqGS:IAS), if they purchased the Company's shares between March 2, 2023 and February 27, 2024, inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/icon-public-limited-company-lawsuit-submission-form?prid=138445&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / March 24, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 5, 2025 to file lead plaintiff applications in a securities class action lawsuit against e.l.f.

Investors should consider the iShares Core S&P Total U.S. Stock Market ETF and its portfolio of 2,506 companies for broad stock market exposure & diversification. In many respects, the ITOT and VTI ETFs are virtually identical, despite the VTI ETF having over 1,000 more companies in its portfolio. Both ETFs have the same very affordable expense fee (0.03%) and both have delivered strong 10-year total returns.

NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / March 24, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 16, 2025 to file lead plaintiff applications in a securities class action lawsuit against The Bancorp, Inc. ("Bancorp" or the "Company") (NasdaqGS:TBBK), if they purchased the Company's securities between January 25, 2024 and March 4, 2025, inclusive (the "Class Period").